MILFORD, Massachusetts, USA – June 3, 2026
Waters Corporation has announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD BACTEC™ FXI Culture System, a next-generation automated blood culture platform designed to improve the speed, consistency, and accuracy of bloodstream infection and sepsis diagnostics. The regulatory milestone enables commercialization of the system in the United States and expands access to advanced microbiology testing capabilities for healthcare institutions. The new platform represents a significant advancement in diagnostic technology, helping laboratories detect bloodstream infections faster while supporting earlier clinical intervention for patients with suspected sepsis. Given the critical importance of rapid diagnosis in life-threatening infections, the FDA clearance positions Waters to strengthen its presence in the global diagnostics market while supporting healthcare providers in improving patient outcomes through faster and more reliable microbiological testing.
Faster Detection Enhances Sepsis and Bloodstream Infection Diagnosis
One of the most significant advantages of the BD BACTEC FXI Culture System is its ability to reduce the time required to detect bloodstream infections. Clinical study data demonstrated that the platform achieved an approximately three-hour faster mean time to detection, representing a 15% improvement compared with the previous-generation BD BACTEC FX Blood Culture System. Faster pathogen detection enables laboratories to deliver earlier diagnostic information to clinicians, supporting quicker initiation of targeted antimicrobial therapies and more informed treatment decisions. This advancement is particularly important in the management of sepsis, a life-threatening condition in which every hour of delayed treatment can significantly increase mortality risk.
By accelerating diagnostic workflows, the new system can help healthcare teams identify infections sooner, optimize therapeutic interventions, and potentially improve survival outcomes for patients experiencing severe bloodstream infections. The FDA clearance therefore highlights the growing role of advanced diagnostics in supporting timely clinical decision-making and enhancing patient care in acute healthcare settings.
Innovative Automation Improves Laboratory Efficiency
Advertisement
The BD BACTEC FXI Culture System introduces several technological innovations designed to address operational challenges faced by modern microbiology laboratories. Among its most notable features is a first-of-its-kind automated gravimetric measurement capability, which objectively verifies blood volume within individual culture vials. This innovation reduces pre-analytical variability and promotes adherence to recommended blood collection practices, helping laboratories maintain greater diagnostic consistency and accuracy. The platform also offers extensive automation through automated vial loading, unloading, incubation, and detection alert functions.
Designed specifically for high-throughput environments, the system provides an industry-leading automated loading capacity of up to 60 vials at a time, representing a 50% increase over competing systems. Available in both 480-vial and 960-vial configurations, the platform supports scalable laboratory operations while minimizing manual intervention and increasing staff productivity. By reducing hands-on workload and maximizing walk-away time, the system enables laboratories to manage increasing testing volumes without compromising operational efficiency or diagnostic quality.
Expanding Global Access to Advanced Diagnostic Technology
The FDA clearance follows recent international regulatory milestones for the BD BACTEC FXI Culture System, including CE marking under the European Union’s In Vitro Diagnostic Regulation (IVDR) and regulatory licensing by Japan’s Pharmaceuticals and Medical Devices Agency. These approvals underscore the growing global demand for rapid and automated diagnostic technologies capable of addressing serious infectious diseases. Waters Corporation emphasized that the platform reflects its commitment to advancing diagnostic innovation and supporting healthcare providers with tools that improve clinical decision-making.
As healthcare systems worldwide continue to prioritize early detection of infectious diseases and antimicrobial stewardship initiatives, technologies such as the BD BACTEC FXI Culture System are expected to play an increasingly important role in modern laboratory medicine. The FDA clearance represents another significant step forward in expanding access to high-performance bloodstream infection diagnostics while reinforcing Waters’ leadership in life sciences and diagnostic innovation.
Source: Waters Corporation press release
